DNA Damage Repair Pathways and Targeted Therapy for Doxorubicin-Resistant Breast Cancer.
Mapping how breast cancers resist chemotherapy reveals specific drug targets that may restore treatment effectiveness in previously resistant tumors.
This review maps how DNA damage repair pathway upregulation drives doxorubicin resistance in breast cancer and catalogues emerging targeted agents that exploit these vulnerabilities. While not providing new primary data, it provides a useful clinical summary of DDR-targeting strategies relevant to the growing problem of anthracycline-resistant breast cancer.
What the study was
- Study design
- Narrative review
- Population
- Patients with doxorubicin-resistant breast cancer
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Frontiers in Bioscience (Landmark Edition)
Why it surfaced
Standard review on DDR and doxorubicin resistance in breast cancer; clinically relevant topic but no new data; score 4/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.